NCCN Guidelines Insights: Colon Cancer, Version 2.2018

View More View Less
  • 1 Robert H. Lurie Comprehensive Cancer Center of Northwestern University; UCSF Helen Diller Family Comprehensive Cancer Center; University of Michigan Comprehensive Cancer Center; UC San Diego Moores Cancer Center; City of Hope Comprehensive Cancer Center; Vanderbilt-Ingram Cancer Center; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; Fox Chase Cancer Center; University of Wisconsin Carbone Cancer Center; Huntsman Cancer Institute at the University of Utah; Fred & Pamela Buffett Cancer Center; Mayo Clinic Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; Moffitt Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; University of Alabama at Birmingham Comprehensive Cancer Center; Stanford Cancer Institute; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; University of Colorado Cancer Center; Dana-Farber/Brigham & Women's Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Roswell Park Comprehensive Cancer Center; Memorial Sloan Kettering Cancer Center; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; The University of Texas MD Anderson Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Duke Cancer Institute; and National Comprehensive Cancer Network.
Restricted access

The NCCN Guidelines for Colon Cancer provide recommendations regarding diagnosis, pathologic staging, surgical management, perioperative treatment, surveillance, management of recurrent and metastatic disease, and survivorship. These NCCN Guidelines Insights summarize the NCCN Colon Cancer Panel discussions for the 2018 update of the guidelines regarding risk stratification and adjuvant treatment for patients with stage III colon cancer, and treatment of BRAF V600E mutation–positive metastatic colorectal cancer with regimens containing vemurafenib.

Provided content development and/or authorship assistance.

Supplementary Materials

    • Supplemental Material (PDF 211 KB)
All Time Past Year Past 30 Days
Abstract Views 4 0 0
Full Text Views 19328 11111 996
PDF Downloads 6394 4098 377
EPUB Downloads 0 0 0